American Society of Hirudotherapy

Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation

Research article published in Journal of cardiac surgery (2020)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Observational studyClinical LiteratureDrug DevelopmentKaseer et al. · Journal of cardiac surgery, 2020

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) induces hemostatic alterations that may contribute to hematological complications. Unfractionated heparin (UFH) is the mainstay antithrombotic in ECMO and depends on antithrombin III (AT III) to exhibit its actions. However, it bears the risk for heparin-induced thrombocytopenia. Bivalirudin is a direct thrombin inhibitor and is inherently not dependent on AT III. AIM OF THE STUDY: To assess the efficacy and safety profiles of UFH compared with bivalirudin during ECMO support. METHODS: We retrospectively reviewed 52 adult patients who were supported by ECMO from 1 January 2013 to 1 September 2018. Among them, 33 received UFH and 19 received bivalirudin. We analyzed their 7-day rate of composite thrombotic, bleeding, and mortality episodes while on anticoagulation. RESULTS: There were no statistical differences in the 7-day rate of composite thrombosis (33.3% vs 26.3%; P = 0.60), major bleeding (18.2% vs 5.3%; P = .24), 30-day mortality, (42.4% vs 26.3%; P = .37), or in-hospital mortality (45.5% vs 36.8%; P = .58). The percentage of time activated partial thromboplastin time (aPTT) was within the therapeutic range was higher with bivalirudin (50% vs 85.7%; P = .007). CONCLUSIONS: This study suggests that UFH and bivalirudin are associated with similar rates of thrombosis, major bleeding, and mortality events in patients supported by ECMO. However, it was observed that bivalirudin consistently maintained aPTT within the therapeutic range in comparison to UFH.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleObservational Study
Indexed MeSH termsAdolescentAdultAgedAged, 80 and overAnticoagulantsExtracorporeal Membrane OxygenationFemaleHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsRecombinant ProteinsRetrospective StudiesThrombocytopeniaThrombosisYoung Adult

Summary

In this retrospective study of 52 ECMO patients (33 heparin, 19 bivalirudin), 7-day thrombosis and bleeding rates and 30-day and in-hospital mortality did not differ, but bivalirudin kept aPTT within therapeutic range more often than heparin (85.7% vs 50%; P = .007).

Why This Matters for Hirudotherapy

Kaseer et al. (2020, J. Card. Surg.) retrospectively reviewed 52 adult ECMO patients (33 on unfractionated heparin, 19 on bivalirudin) and found no statistically significant differences in 7-day composite thrombosis, major bleeding, or mortality, while bivalirudin more consistently kept aPTT within the therapeutic range (50% vs 85.7% of time, P = .007). The hirudotherapy connection is conceptual and mechanistic: bivalirudin is a direct thrombin inhibitor that, unlike heparin, does not depend on antithrombin III — the same direct-thrombin-inhibition principle embodied by the leech-derived peptide hirudin (the PubMed keyword set for this record even lists "Hirudins"), illustrating how the medicinal-leech secretome inspired a recognized class of anticoagulants. Honest caveats: this is a small, single-center retrospective comparison (not a randomized trial), it studies the synthetic agent bivalirudin rather than leech therapy or native hirudin, and it draws no conclusions about hirudotherapy.

Citation

Reference (Vancouver style)

Kaseer H, Soto-Arenall M, Sanghavi D, Moss J, Ratzlaff R, Pham S, et al. Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. J Card Surg. 2020;35(4):779-786. doi:10.1111/jocs.14458. PMID: 32048330

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.